Compare AbbVie Inc (ABBV) vs GE Aerospace (GE) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

GE trades at $378.68, up 0.31% today, with a bullish technical signal from moving averages and strong support at $375. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $1.86 exceeding expectations. Revenue grew to $45.86 billion in 2025, while net income margin improved to 17.86%. Recent news highlights robust order growth in aerospace and defense contracts, including a U.S. Air Force engine development deal announced May 19, 2026.

Outlook remains positive with a consensus price target of $394.33, though high valuation ratios (P/E 47.04) and rising debt levels pose risks. Aerospace demand and defense contracts support growth, but investors should monitor execution on expansion investments and macroeconomic pressures on aviation.